|Articles|July 27, 2007

HemoBioTech Engages CRO to Facilitate Clinical Study in India of its Human Blood Substitute, HemoTech

DALLAS, TX, June 21, 2007-HemoBioTech (OTCBB: HMBT.OB) announced today that it has engaged Paragon Biomedical (www.parabio.com) to provide regulatory and clinical services in India related to the Company’s proposed human blood substitute, HemoTech. Paragon will submit preclinical data regarding HemoTech studies that were part of a European IND and clinical data related to the HemoTech human study in Zaire to the Indian regulatory agency for review. The goal is to receive permission to commence clinical studies of HemoTech in India.

A limited clinical study of HemoTech was performed in 1991 at the Institute de la Recherche en Sciences de la Sante, Centre de l’Anemie S.S. in Zaire. Nine sickle cell anemia patients were infused with amounts of HemoTech representing 25% of patients’ total blood volume. This limited clinical trial resulted in significant patient improvement and suggested that HemoTech: 1) can work as a physiological oxygen carrier in humans; 2) is non-toxic; 3) is vasodilatory and anti-inflammatory; and 4) induces red blood cell production (erythropoiesis). Peripheral blood reticulocytes increased from 4% to 49%.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

© photon_photo - © photon_photo - stock.adobe.com

October 22nd, 2026

Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology

Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.

© putilov_denis - © putilov_denis - stock.adobe.com

October 21st, 2026

Obesity Is More Than Weight: Practical Approaches to Managing Comorbidities in Clinical Research

Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.

October 21st, 2026

What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight

In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.

October 14th, 2026

Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection

Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.